// App-Quantinova.ai

99 : Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors

Researchers

Presenter

  • Emily Hinchcliff

Principal Investigators

  • Bryan Fellman

  • Ying Yuan

  • Manoj Chelvanambi

  • Jen Wargo

  • Yan Liu

  • Jinsong Liu

  • Sanghoon Lee

  • Jason Roszik

  • Robert Hillman

  • Shannon Westin

  • Anil Sood

  • Pamela Soliman

  • Michael Frumovitz

  • Aaron Shafer

  • Larissa Meyer

  • Nicole Fleming

  • David Gershenson

  • David Vining

  • Dhakshina Ganeshan

  • Patrick Hwu

  • Karen Lu

  • Amir Jazaeri

Medical Centers

  • Sungkyunkwan University School of Medicine, Seoul, South Korea

  • Yonsei University College of Medicine, Seoul, South Korea

  • College of Life Science, CHA University, Seongnam, South Korea

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear-cell adenocarcinoma

Biomarkers

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Ticilimumab

  • Durvalumab

  • Ipilimumab

  • Nivolumab

Outcome

  • Unknown

Study Design

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved